The Perils of Pull-Through
Listen on: Apple Podcasts or Spotify
A new drug has made it to the insurer’s formulary, but will providers actually prescribe it?
Pull-through challenges abound; getting physicians to prescribe a therapy means training and coordinating field staff, encouraging pharmacies to stock and recommend the medication, educating patients, and more. Then there’s the challenge of measuring success – what does successful pull-through look like anyway?
Most market access teams at pharmaceutical and biotech manufacturers have the same problem: evidence of clinical effectiveness isn’t always enough to affect prescribing behavior, often due to – accurate or misperceived – affordability concerns.
Is there anything manufacturers can do to positively impact pull-through for their products? In this episode of the IDI Podcast, Jack Timko, Senior Principal, Valuate Health Consultancy, discusses the perils of pull-through in market access and shares how data may be the answer. “The inability to ‘pull through’ a prescription, despite HCP field team engagement and educational efforts, has remained a top concern of our clients during my 15 years in the market access space,” says Timko. Listen on: Apple Podcasts or Spotify
Archbow Consulting, Entrée Health, and Valuate Health Consultancy are sister companies under the Value and Access division of Omnicom Health Group. Learn more about our united organizations here.
For additional insights on this topic, you may also enjoy the following:
Related Blog Posts:
Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe design, build, and optimize product distribution and patient access strategies. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn, Twitter or subscribing to this blog which you can do below.